REDDING, Calif., July 10, 2024 /PRNewswire/ -- According to a new market research report titled, 'Recombinant Coagulation Factors Market Size, Share, Forecast, & Trends Analysis by Type (Factor VIII, Factor IX), Source (CHO, HEK), Application (Hemophilia (Type A, Type B), Others), End User (Hospitals, CRO)- Global Forecast to 2031,' published by Meticulous Research^®, the recombinant coagulation factors market is projected to reach $26.29 billion by 2031, at a CAGR of 8.6% from 2024 to 2031.

Download Sample Report Now- https://www.meticulousresearch.com/download-sample-report/cp_id=1254 

Recombinant coagulation factors are glycoproteins produced by recombinant DNA technology. They are mainly used for the treatment of various coagulation disorders. They are gaining popularity due to their benefits, such as reduced risk of bloodborne disease transmission and effective treatment.

The increasing prevalence of hemophilia and other bleeding disorders, growing R&D for coagulation factors, growing awareness about the benefits of the recombinant coagulation factors, and increasing prophylactic treatment for hemophilia across the globe are driving the growth of the recombinant coagulation factors market. However, the high cost of recombinant factors compared to plasma-derived factors and the limited accessibility & availability of recombinant clotting factors in developing & underdeveloped countries are expected to restrain the growth of this market.

Furthermore, untapped markets in emerging economies and rising healthcare expenditure are expected to create market growth opportunities. However, challenges in the production of recombinant coagulation factors, stringent regulatory requirements, lack of reimbursement in some countries, and lack of awareness among patients are some of the challenges impacting the market's growth.

Get a Glimpse Inside: Request Sample Pages- https://www.meticulousresearch.com/request-sample-report/cp_id=1254 

Increased Prevalence of Infectious Diseases and Rising Need to Reduce Transmission of Bloodborne Disease to Drive the Growth of this Market

There is a rising prevalence of infectious diseases globally. Infectious diseases such as hepatitis B virus, hepatitis C virus, and human immunodeficiency virus are highly infectious and can be transmitted through blood. Utilizing blood-derived coagulation factors carries a high risk of transmitting infectious diseases. This has created a need for safer treatment options for the treatment of various coagulation disorders. In this regard, recombinant factor VIII was first introduced in the 1980s. Recombinant coagulation factors are not derived from blood and are manufactured in the laboratory using recombinant DNA technology. This avoids the risk of transmission of bloodborne disease and facilitates safer treatment for various coagulation disorders.

The key players profiled in this market study are Baxter International Inc. (U.S.), Grifols, S.A. (Spain), CSL Limited (Australia), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen Inc. (U.S.), Bayer AG (Germany), Kedrion S.p.A. (Italy), Emergent BioSolutions (U.S.), and Pfizer Inc. (U.S.).

The recombinant coagulation factors market is segmented based on Type (Recombinant Factors VIII, Recombinant Factor IX, and Other Types), Source (Chinese Hamster Ovary (CHO) Cell Line, Human Embryonic Kidney (HEK) Cell Line, and Other Sources), Application (Hemophilia A, Hemophilia B, and Other Applications), End User (Hospitals & Clinics and Clinical Research Laboratories), and Geography. The study also evaluates industry competitors and analyzes their market shares at the country and regional levels. The study also provides valuable insights into the key growth strategies adopted by major market players in the last three to four years.

Have Specific Research Needs? Request a Customized Report- https://www.meticulousresearch.com/request-customization/cp_id=1254 

Based on type, in 2024, the recombinant factor VIII segment is expected to account for the largest share of 59.5% of the recombinant coagulation factors market. This segment's large market share is attributed to the high prevalence of hemophilia A, the high efficacy of recombinant factors VIII, and an established market presence of recombinant factor VIII products.

Based on source, in 2024, the Chinese hamster ovary (CHO) cell line segment is expected to account for the largest share of the recombinant coagulation factors market. This segment's large share is attributed to the high popularity of the CHO cell lines for the production of biologics, the high similarity of the CHO cells to the human cell system, and high reproducibility.

Based on application, in 2024, the Hemophilia A segment is estimated to account for the largest share of 64.3% of the recombinant coagulation factors market. This segment's large market share can be attributed to the rising number of patients with hemophilia A, increased awareness about advanced treatment options, and the high efficacy of recombinant coagulation factors in treating hemophilia A.

Based on end user, in 2024, the hospitals & clinics segment is estimated to account for the largest share of the recombinant coagulation factors market. This segment's large share can be attributed to the high adoption of recombinant coagulation factors by hospitals & clinics, rising healthcare expenditures, and growing awareness among healthcare professionals.

Based on geography, in 2024, North America is expected to account for the largest share of 43.4% of the recombinant coagulation factor market, followed by Europe and Asia-Pacific. North America's significant market share can be attributed to the robust healthcare infrastructure in the region, high healthcare expenditure, technological advancements, favorable reimbursement policies, high awareness, and the presence of key market players in the region.

The report also includes an extensive assessment of the key growth strategies adopted by leading market players over the past three to four years. In the last couple of years, the recombinant coagulation factors market has witnessed various developments.

Browse In-depth Report Now- https://www.meticulousresearch.com/product/recombinant-coagulation-factors-market-1254 

Scope of the Report:

Recombinant Coagulation Factors Market Assessment—by Type

• Recombinant Factor VIII
• Recombinant Factor IX
• Other Types

Note: Other types include recombinant factor XIII, VIIa, and X

Recombinant Coagulation Factors Market Assessment—by Source

• Chinese Hamster Ovary (CHO) Cell Line
• Human Embryonic Kidney (HEK) Cell Line
• Other Sources

Note: Other sources include the Baby hamster kidney (BHK) cell line and COS cell line

Recombinant Coagulation Factors Market Assessment—by Application

• Hemophilia A
• Hemophilia B
• Other Applications

Recombinant Coagulation Factors Market Assessment—by End User

• Hospitals & Clinics
• Clinical Research Laboratories

Recombinant Coagulation Factors Assessment—by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Spain
  • Netherlands
  • Sweden
  • Rest of Europe (RoE)
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa

Unlock Opportunities: Buy Now- https://www.meticulousresearch.com/Checkout/95626007 

Related Reports:

Plasma Therapy Market by Type (Pure Platelet-rich Plasma, Platelet-rich Fibrin), Application (Orthopedics, Dermatology, Cosmetology, Rheumatology, Ophthalmology), End User (Hospitals and Clinics, Research Institutes) - Global Forecast to 2028

Cell Culture Reagents Market by Product (Growth Factors and Cytokines, Supplement, Cryoprotective, Antibiotic, Buffer), Application (Bioproduction (Antibody, Protein, Vaccine), Research, Diagnostics), End User (Pharma, Academic) - Global Forecast to 2029

Competent Cells Market by Type (Cloned Competent Cells, Agrobacterium Tumefaciens Competent Cells, and Expression Competent Cells), Treatment (Chemically Competent Cells and Electrocompetent Cells), Application (Cloning, Protein Expression, others), and by End User (Pharmaceutical and Biotechnology Industry, Academic and Research Institutes, and Contract Research Organizations) - Global Forecasts to 2023

About Meticulous Research®

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Content Source: https://www.meticulousresearch.com/pressrelease/326/recombinant-coagulation-factors-market-2031

Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg

View original content:https://www.prnewswire.com/news-releases/recombinant-coagulation-factors-market-to-be-worth-26-29-billion-by-2031---exclusive-report-by-meticulous-research-302192028.html

SOURCE Meticulous Market Research Pvt. Ltd.